JP2018508219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508219A5 JP2018508219A5 JP2017546715A JP2017546715A JP2018508219A5 JP 2018508219 A5 JP2018508219 A5 JP 2018508219A5 JP 2017546715 A JP2017546715 A JP 2017546715A JP 2017546715 A JP2017546715 A JP 2017546715A JP 2018508219 A5 JP2018508219 A5 JP 2018508219A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- item
- extracellular
- seq
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 175
- 108020001507 fusion proteins Proteins 0.000 claims description 175
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 121
- 108020004707 nucleic acids Proteins 0.000 claims description 79
- 102000039446 nucleic acids Human genes 0.000 claims description 79
- 150000007523 nucleic acids Chemical class 0.000 claims description 79
- 230000003834 intracellular effect Effects 0.000 claims description 62
- 230000002209 hydrophobic effect Effects 0.000 claims description 55
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 52
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 52
- 230000004068 intracellular signaling Effects 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 38
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 37
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 34
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 25
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 23
- 102000017578 LAG3 Human genes 0.000 claims description 23
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 22
- 108091008874 T cell receptors Proteins 0.000 claims description 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 22
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 19
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 19
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 16
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 16
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 16
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 16
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 12
- 230000000139 costimulatory effect Effects 0.000 claims description 11
- -1 CD300 Proteins 0.000 claims description 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 10
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 8
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 claims description 8
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 8
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 8
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 claims description 8
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000009149 molecular binding Effects 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 6
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 4
- 102100031351 Galectin-9 Human genes 0.000 claims description 4
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102000007497 Patched-2 Receptor Human genes 0.000 claims description 4
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 2
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims description 2
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 210000000428 immunological synapse Anatomy 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000008160 Cyclin A1 Human genes 0.000 description 2
- 108010060267 Cyclin A1 Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100022748 Wilms tumor protein Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000057542 human CD200R1 Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128979P | 2015-03-05 | 2015-03-05 | |
| US62/128,979 | 2015-03-05 | ||
| PCT/US2016/021064 WO2016141357A1 (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory fusion proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081118A Division JP7026161B2 (ja) | 2015-03-05 | 2020-05-01 | 免疫調節性融合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508219A JP2018508219A (ja) | 2018-03-29 |
| JP2018508219A5 true JP2018508219A5 (enExample) | 2019-04-11 |
| JP6917896B2 JP6917896B2 (ja) | 2021-08-18 |
Family
ID=55587371
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546715A Active JP6917896B2 (ja) | 2015-03-05 | 2016-03-04 | 免疫調節性融合タンパク質およびその使用 |
| JP2020081118A Expired - Fee Related JP7026161B2 (ja) | 2015-03-05 | 2020-05-01 | 免疫調節性融合タンパク質およびその使用 |
| JP2021150184A Active JP7441201B2 (ja) | 2015-03-05 | 2021-09-15 | 免疫調節性融合タンパク質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081118A Expired - Fee Related JP7026161B2 (ja) | 2015-03-05 | 2020-05-01 | 免疫調節性融合タンパク質およびその使用 |
| JP2021150184A Active JP7441201B2 (ja) | 2015-03-05 | 2021-09-15 | 免疫調節性融合タンパク質およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180044404A1 (enExample) |
| EP (2) | EP4406604A3 (enExample) |
| JP (3) | JP6917896B2 (enExample) |
| KR (1) | KR20170120701A (enExample) |
| CN (1) | CN107531805A (enExample) |
| AU (3) | AU2016226022B2 (enExample) |
| BR (1) | BR112017018919A8 (enExample) |
| CA (2) | CA2978186A1 (enExample) |
| ES (1) | ES2979088T3 (enExample) |
| HK (1) | HK1246317A1 (enExample) |
| IL (1) | IL254165B (enExample) |
| MX (4) | MX2017011201A (enExample) |
| MY (2) | MY196588A (enExample) |
| RU (1) | RU2755227C2 (enExample) |
| SA (1) | SA517382216B1 (enExample) |
| SG (2) | SG10201908203SA (enExample) |
| WO (1) | WO2016141357A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
| BR112017008693A2 (pt) | 2014-10-31 | 2018-02-27 | The Trustees Of The University Of Pennsylvania | célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. |
| MY196588A (en) | 2015-03-05 | 2023-04-19 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins and uses Thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| US11026969B2 (en) | 2015-12-23 | 2021-06-08 | Fred Hutchinson Cancer Research Center | High affinity T cell receptors and uses thereof |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018009972A1 (en) * | 2016-07-14 | 2018-01-18 | Peter Maccallum Cancer Institute | Chimeric antigen receptor modified t cells |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| US20190352363A1 (en) | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110267666A (zh) * | 2016-12-22 | 2019-09-20 | 温德弥尔治疗公司 | 用于调节免疫系统的组合物和方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| CN110621335B (zh) | 2017-03-17 | 2025-06-03 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| AU2018246235B2 (en) | 2017-03-27 | 2023-12-21 | National University Of Singapore | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CA3071860A1 (en) | 2017-08-02 | 2019-02-07 | Phanes Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| GB2578394A (en) | 2017-08-07 | 2020-05-06 | Univ California | Platform for generating safe cell therapeutics |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20200064083A (ko) * | 2017-09-07 | 2020-06-05 | 큐 바이오파마, 인크. | 항원-제시 폴리펩티드 및 이의 사용 방법 |
| WO2019055862A1 (en) | 2017-09-14 | 2019-03-21 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| EP3707248A4 (en) * | 2017-11-10 | 2021-08-18 | Chineo Medical Technology Co., Ltd. | MODIFIED IMMUNE CELLS AND THEIR USES |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019193476A1 (en) | 2018-04-02 | 2019-10-10 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3810172A4 (en) * | 2018-06-21 | 2022-04-20 | Shattuck Labs, Inc. | Heterodimeric proteins and uses thereof |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102261407B1 (ko) * | 2018-10-10 | 2021-06-08 | 한국화학연구원 | Hvem을 표적으로 하는 키메라 항원 수용체 |
| US20210393692A1 (en) * | 2018-11-13 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| TWI856047B (zh) | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US12448430B2 (en) | 2019-03-11 | 2025-10-21 | Fred Hutchinson Cancer Center | High avidity WT1 T cell receptors and uses thereof |
| WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| MX2021011373A (es) * | 2019-03-21 | 2022-01-06 | Onk Therapeutics Ltd | Celulas efectoras inmunitarias modificadas con mayor resistencia a la muerte celular. |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| US12497453B2 (en) * | 2019-09-27 | 2025-12-16 | Nanjing Immunophage Biotech Co., Ltd. | ROR1 specific chimeric antigen receptors and their therapeutic applications |
| JP2023504043A (ja) * | 2019-11-27 | 2023-02-01 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｋ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ |
| EP4066842A4 (en) * | 2019-11-29 | 2023-01-25 | Suzhou Nova Therapeutics Co. Ltd | APPLICATION OF CAR-T CELLS IN MANUFACTURE OF DRUG FOR TREATMENT OF CANCER |
| GB2608279B (en) * | 2019-12-11 | 2024-08-28 | Myeloid Therapeutics Inc | Therapeutic cell compositions and methods for manufacture and uses thereof |
| EP4431110A3 (en) * | 2020-01-19 | 2025-01-15 | Chineo Medical Technology Co., Ltd. | Enhanced receptor for improving immune cell function |
| GB202101491D0 (en) * | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| EP4132962A1 (en) * | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| CN115315439A (zh) * | 2020-04-09 | 2022-11-08 | 奥托路斯有限公司 | 细胞 |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR20230013257A (ko) * | 2020-05-22 | 2023-01-26 | 충칭 프리시젼 바이오테크 컴퍼니 리미티드 | 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용 |
| WO2022016112A1 (en) | 2020-07-17 | 2022-01-20 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| US20230295564A1 (en) * | 2020-07-23 | 2023-09-21 | Emory University | Galectin-9 Specific Binding Agents for Use in Treating Cancer |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| US20240252613A1 (en) * | 2021-05-20 | 2024-08-01 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
| WO2022266192A1 (en) | 2021-06-16 | 2022-12-22 | Instil Bio, Inc. | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| EP4476246A2 (en) * | 2022-02-07 | 2024-12-18 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding |
| JP2025541309A (ja) * | 2022-12-15 | 2025-12-18 | カリヴィル イムノセラピューティクス， インコーポレイテッド | Ｃｄ４７／ｓｉｒｐ－アルファ免疫チェックポイント阻害剤の組成物およびその使用 |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| EP4599843A1 (en) | 2024-02-09 | 2025-08-13 | Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau | Car and modified cd200r combination |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1999A (en) | 1841-03-12 | Improvement in seed-planters | ||
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| PT737207E (pt) | 1994-01-11 | 2005-02-28 | Dyax Corp | Inibidores de plasmina humana derivados de dominios kunitz |
| US6083751A (en) | 1994-11-01 | 2000-07-04 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| ES2323651T3 (es) | 2005-01-05 | 2009-07-22 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Dominios sinteticos de inmunoglobulina con propiedades de union elaborados por ingenieria en regiones de la molecula diferentes de las regiones que determinan la complementariedad. |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| EP2198022B1 (en) | 2007-09-24 | 2024-03-06 | University Of Zurich | Designed armadillo repeat proteins |
| US9163258B2 (en) * | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| WO2012042480A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6203705B2 (ja) * | 2011-03-23 | 2017-09-27 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための方法および組成物 |
| AU2012240135B2 (en) | 2011-04-08 | 2016-09-08 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2014106839A1 (en) | 2013-01-01 | 2014-07-10 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| US20160008399A1 (en) * | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CN103965361B (zh) | 2013-02-06 | 2018-10-30 | 上海细胞治疗工程技术研究中心集团有限公司 | 一种t细胞信号的嵌合分子转换器及其用途 |
| JP6578271B2 (ja) | 2013-04-17 | 2019-09-18 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫抑制ＴＧＦ−βシグナルコンバーター |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| EP3172234B1 (en) | 2014-07-21 | 2020-04-08 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| EP3177314B1 (en) * | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| WO2016024021A1 (en) * | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| BR112017013690A2 (pt) | 2014-12-24 | 2018-03-06 | Ucl Business Plc | célula |
| US10350245B2 (en) * | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| MY196588A (en) | 2015-03-05 | 2023-04-19 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins and uses Thereof |
| EP3310805B1 (en) | 2015-06-19 | 2021-02-17 | Kobold, Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
| EP3380117B1 (en) | 2015-11-27 | 2021-01-06 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
| US11026969B2 (en) * | 2015-12-23 | 2021-06-08 | Fred Hutchinson Cancer Research Center | High affinity T cell receptors and uses thereof |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| CN109312304A (zh) * | 2016-04-20 | 2019-02-05 | 弗雷德哈钦森癌症研究中心 | 免疫调节性il2r融合蛋白及其用途 |
| CN110621335B (zh) * | 2017-03-17 | 2025-06-03 | 弗雷德哈钦森癌症中心 | 免疫调节融合蛋白及其用途 |
| WO2019061012A1 (zh) | 2017-09-26 | 2019-04-04 | 南京凯地生物科技有限公司 | 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用 |
| CN110330567B (zh) | 2019-07-02 | 2020-11-06 | 南京凯地生物科技有限公司 | 双特异性嵌合抗原受体t细胞，其制备方法和应用 |
-
2016
- 2016-03-04 MY MYPI2021007596A patent/MY196588A/en unknown
- 2016-03-04 SG SG10201908203S patent/SG10201908203SA/en unknown
- 2016-03-04 CN CN201680023758.4A patent/CN107531805A/zh active Pending
- 2016-03-04 CA CA2978186A patent/CA2978186A1/en active Pending
- 2016-03-04 MY MYPI2017001281A patent/MY189195A/en unknown
- 2016-03-04 RU RU2017133637A patent/RU2755227C2/ru active
- 2016-03-04 EP EP24169396.9A patent/EP4406604A3/en not_active Withdrawn
- 2016-03-04 SG SG11201707182WA patent/SG11201707182WA/en unknown
- 2016-03-04 AU AU2016226022A patent/AU2016226022B2/en not_active Ceased
- 2016-03-04 JP JP2017546715A patent/JP6917896B2/ja active Active
- 2016-03-04 HK HK18105732.2A patent/HK1246317A1/zh unknown
- 2016-03-04 ES ES16711081T patent/ES2979088T3/es active Active
- 2016-03-04 CA CA3177938A patent/CA3177938A1/en active Pending
- 2016-03-04 US US15/555,951 patent/US20180044404A1/en not_active Abandoned
- 2016-03-04 MX MX2017011201A patent/MX2017011201A/es unknown
- 2016-03-04 WO PCT/US2016/021064 patent/WO2016141357A1/en not_active Ceased
- 2016-03-04 KR KR1020177027794A patent/KR20170120701A/ko active Pending
- 2016-03-04 EP EP16711081.6A patent/EP3265481B1/en active Active
- 2016-03-04 BR BR112017018919A patent/BR112017018919A8/pt not_active Application Discontinuation
-
2017
- 2017-08-27 IL IL254165A patent/IL254165B/en unknown
- 2017-08-30 SA SA517382216A patent/SA517382216B1/ar unknown
- 2017-08-31 MX MX2022006002A patent/MX2022006002A/es unknown
- 2017-08-31 MX MX2022006004A patent/MX2022006004A/es unknown
- 2017-08-31 MX MX2022006006A patent/MX2022006006A/es unknown
-
2020
- 2020-05-01 JP JP2020081118A patent/JP7026161B2/ja not_active Expired - Fee Related
- 2020-09-30 AU AU2020244495A patent/AU2020244495B2/en not_active Ceased
-
2021
- 2021-02-03 US US17/166,903 patent/US12012443B2/en active Active
- 2021-09-15 JP JP2021150184A patent/JP7441201B2/ja active Active
-
2022
- 2022-11-16 AU AU2022271411A patent/AU2022271411A1/en not_active Abandoned
-
2024
- 2024-05-07 US US18/657,687 patent/US20250109180A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508219A5 (enExample) | ||
| JP2020511136A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2022113880A5 (enExample) | ||
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| Weinkove et al. | Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations | |
| De Sousa Linhares et al. | Not all immune checkpoints are created equal | |
| US20240425565A1 (en) | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | |
| Georgiev et al. | Coming of age: CD96 emerges as modulator of immune responses | |
| US11180553B2 (en) | Chimeric antigen receptor | |
| Pentcheva‐Hoang et al. | Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections | |
| JP2021177771A5 (enExample) | ||
| JP2019515672A5 (enExample) | ||
| JP2019513394A5 (enExample) | ||
| WO2017176525A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2017527310A5 (enExample) | ||
| CN108513576A (zh) | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 | |
| JP2018525006A5 (enExample) | ||
| JP2017519502A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| JP2017518071A5 (enExample) | ||
| Wu et al. | Immunotherapies: the blockade of inhibitory signals | |
| US11484572B2 (en) | Use of HLA-B27 homodimers for cancer treatment | |
| Tal et al. | An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities |